Pamidronate
Pamidronate (Aredia) was the first bisphosphonate infusion widely used in cancer, for high calcium levels and for bone damage from myeloma and breast cancer; zoledronic acid has largely replaced it because it is quicker to give.
Overview
Pamidronate disodium was approved in October 1991 for moderate or severe hypercalcaemia of malignancy with or without bone metastases and later for osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma in conjunction with standard antineoplastic therapy, on placebo-controlled trials (Hortobagyi 1996, Berenson 1996) that roughly halved skeletal complications. The two-hour infusion, compared with fifteen minutes for zoledronic acid, and the pivotal head-to-head hypercalcaemia trials led most centres to switch, although pamidronate remains a lower-cost generic option and is preferred by some in myeloma because of a lower rate of osteonecrosis of the jaw in observational series. Renal toxicity with rapid infusion, acute-phase reactions and jaw osteonecrosis are the key risks.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 1991 | Hypercalcaemia of malignancy |
| US | 1995 | Osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma, with antineoplastic therapy |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Pamidronate" OR ABSTRACT:"Pamidronate" OR TITLE:"Aredia" OR ABSTRACT:"Aredia" OR TITLE:"historic" OR ABSTRACT:"historic") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pamidronate, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductIbandronic acid
Shares Zoledronic acid, Denosumab, Bone-modifying agents (bisphosphonates, denosumab), HR-positive / HER2-negative breast cancer and the tag supportive.
- TargetRANK ligand (RANKL)
Shares Denosumab, Bone-modifying agents (bisphosphonates, denosumab), Multiple myeloma, HR-positive / HER2-negative breast cancer.
- ProductMegestrol acetate
Shares HR-positive / HER2-negative breast cancer and the tags nci-list, generic, supportive.
- ProductDexamethasone
Shares Multiple myeloma and the tags nci-list, generic, supportive.
- ProductGranisetron
Shares the tags nci-list, generic, supportive.
- ProductMesna
Shares the tags nci-list, generic, supportive.
- ProductOndansetron
Shares the tags nci-list, generic, supportive.
- ProductPrednisone
Shares the tags nci-list, generic, supportive.